Cover -- Title -- Copyright -- End User License Agreement -- Contents -- Foreword -- Preface -- List of Contributors -- Redox Signaling, Oxidative Stress in Cardiovascular Disease -basic Science and Clinical Aspects -- Bashir M. Matata1,* and Maqsood M. Elahi2 -- INTRODUCTION -- Reactive Oxygen Species and Reactive Nitrogen Species -- Nitric Oxide Synthases and the Generation of Reactive Nitrogen Species -- Potential Sources of Reactive Oxygen Species (ROS) -- Enzymatic Generation of NADPH Oxidase as a Source of ROS -- The Mechanisms of Assembly and Activation of NOX Enzymes -- The Biological Effect of NOX-activation -- Defects in the NOX System and its Consequences -- Intracellular Reactive Oxidant Species as By-products of Mitochondrial Respiration -- Generation of Reactive Oxidant Species by the Xanthine Oxidoreductase System -- NOS Uncoupling as a Source of Reactive Oxidant Species in the Cell -- Redox Signalling Pathways -- ROS Signalling as the Mechanism for NF-(Sm(BB Activation -- ROS Signalling via Ap-1 Activation -- ROS Signalling via Peroxisome Proliferators Activated Receptors (PPAR) -- CONCLUDING REMARKS -- LIST OF ABBREVIATIONS -- ACKNOWLEDGEMENT -- REFERENCES -- Oxidative Stress and Leukocytes Activation - The Two Keystones of Ischemia/Reperfusion Injury during Myocardial Infarction, Valve Disease, and Atrial Fibrillation -- Bashir M. Matata1,* and Maqsood M. Elahi2 -- INTRODUCTION -- Oxidative Stress as a Putative Mechanism for Atherogenesis and Myocardial Injury -- Interaction Between Circulating Leukocytes, ROS and the Antioxidant Systems -- Hypertension -- Aortic Valve Disease -- Atrial Fibrillation -- Atherosclerosis and Premature Coronary Artery Disease (CAD) -- Diabetes -- Stroke -- Heart Failure -- The Role of Antioxidants -- CONCLUSION -- LIST OF ABBREVIATIONS -- ACKNOWLEDGEMENT -- REFERENCES.

Lipids, Oxidation, and Cardiovascular Disease -- Priscilla Day-Walsh1,* -- INTRODUCTION -- PATHWAYS INVOLVED IN CHOLESTEROL METABOLISM AND TRANSPORT -- Chylomicrons -- Chylomicron Remnants -- Very Low-Density Lipoproteins -- Intermediate Density Lipoproteins (IDL) -- Low-Density Lipoproteins (LDL) -- Lipoprotein(a) (Lp(a)) -- High-Density Lipoproteins (HDL) -- FFA Metabolism Through Mitochondrial Beta-oxidation -- Lipoproteins and Lipid Oxidation -- Enzymatic Lipid Oxidation -- Regulation of Cholesterol Synthesis and Metabolism -- Reverse Cholesterol Transport and Cholesterol Metabolism to Bile Acids -- CLINICAL TRIALS TARGETING CHOLESTROL METABOLISM -- CONCLUDING REMARKS -- ACKNOWLEDGEMENT -- REFERENCES -- Maternal Factors and the Placenta: A Programming Environment for Cardiovascular Disease -- Wai Lok Whitney Ching1, Priscilla Day-Walsh2 and Amanda Sferruzzi-Perri1,* -- INTRODUCTION -- The Maternal Environment and Programming of Cardiovascular Disease -- The Placenta, Fetal Outcomes, and CVD Programming -- Oxidative Stress and Lipid Oxidation -- The Influence of the Maternal Microbiome on Developmental Programming -- Genetic and Epigenetic Regulation in Fetal Programming and CVD -- Single Nucleotide Polymorphisms -- MicroRNAs -- Epigenetics: DNA Methylation and Histone Modifications -- CONCLUSION -- ACKNOWLEDGEMENT -- REFERENCES -- The Emerging Role of Microbiome in Cardiovascular Diseases -- Emad Shehata1,2 and Priscilla Day-Walsh1,* -- INTRODUCTION -- Microbiome Characteristics in Health and Disease -- Associations of Microbiota and CVD -- Short Chain Fatty Acids in Cardiovascular Disease -- Regulation of Cholesterol and Bile Acids by the Gut Microbiota in CVD -- Metabolism to Coprostanol and Incorporation into Bacterial Membranes -- Impact of Bile Acid Metabolising Bacteria on PH and Amino Acid Sparing.

Interaction of Secondary Bile Acids With Host Receptors -- Choline, L-carnitine, and Their Gut Derived Metabolite Trimethylamine Oxide [TMAO] -- Associations With Other Gut Metabolites -- The Use of Prebiotics and Probiotics to Alter the Microbiome and Prevent CVD -- CONCLUSION -- ACKNOWLEDGEMENT -- REFERENCES -- Oxidants and Antioxidants Interplay in the Modulation of Inflammation and Cardiovascular Disease -- Bashir Matata1,* and Maqsood Elahi2 -- INTRODUCTION -- Oxidative Stress as a Putative Mechanism for CVD -- Molecular Effects of Oxidative Stress -- Oxidative Stress and Programmed Cell Death -- Oxidative Stress and Myocardial Ischaemia-Reperfusion (I/R) Injury -- Antioxidants as a Defence System Against Inflammation and Cardiovascular Disease -- Other Naturally Occurring Antioxidants -- CONCLUSION -- LIST OF ABBREVIATIONS -- ACKNOWLEDGEMENT -- REFERENCES -- Prevention of Reperfusion Injury in Acute Myocardial Infarction: A "flashback" Journey of Novel Strategies Based on the Potential Therapeutic Role of Antioxidants -- Francisco Salazar-Cornejo1, Abraham Gajardo2,3, Marcelo J. Kogan4, 5 and Ram�on Rodrigo3,* -- INTRODUCTION -- PATHOPHYSIOLOGY OF MYOCARDIAL ISCHEMIA-REPERFUSION INJURY -- Sources of Reactive Oxygen and Nitrogen Species in the Heart -- Cardiac Effects of Ischemia and Reperfusion -- ANTIOXIDANTS AS THERAPEUTIC AGENTS -- Ascorbate -- N-acetylcysteine -- Deferoxamine -- Ginger -- Alpha-linolenic Acid -- Nootkatone -- Inonotus obliquus -- Memantine -- Dexmedetomidine -- INTEGRATIVE FOCUS SUPPORTING THE EFFICACY OF A COMBINED ANTIOXIDANT TREATMENT -- CONCLUSION -- LIST OF ABBREVIATIONS -- ACKNOWLEDGEMENT -- REFERENCES -- Improvement of Nitric Oxide Availability in Myocardial Ischemia/reperfusion: Role of Nanotechnology as a Therapeutic Approach.

Marcelo J Kogan1,2,*, Francisco Salazar-Cornejo3, Abraham Gajardo4,5 and Ram�on Rodrigo5,* -- INTRODUCTION -- Oxidative/nitrosative Stress in Myocardial Ischemia/reperfusion: Potential Pharmacological Targets -- THERAPEUTIC FAILURE IN OXIDATIVE STRESS -- DRUG DELIVERY SYSTEM BY NANOPARTICLES -- Targeting strategies -- NANOPARTICLES AND OXIDATIVE STRESS CONTROL IN ISCHEMIA/REPERFUSION -- NITRIC OXIDE DONOR IN CARDIOVASCULAR DISEASE AND NANOPARTICLE APPROACH -- CONCLUDING REMARKS -- LIST OF ABBREVIATIONS -- ACKNOWLEDGEMENTS -- REFERENCES -- Subject Index -- Back Cover.

Blood Oxidant Ties: The Evolving Concepts in Myocardial Injury and Cardiovascular Diseaseis an update on the recent advances in the development of antioxidant-based therapies. It starts with an overview of the mechanisms underlying the genesis of oxidative stress, summarizing the link between oxidative stress and a number of cardiovascular conditions. This is followed by an explanation of how oxidative stress interacts with lipid metabolism and the placental environment. Three chapters on the role of antioxidant-based therapy for cardiovascular diseases round up the book. Key Features- Outlines several cell-signaling pathways that are modulated by the interplay between reducing and oxidizing agents (redox status) and gene expression in the cardiovascular disease process- Brings information about maternal programming environment in the placenta- Covers development of novel nanotechnology-based antioxidant delivery systems for effective drug delivery- Includes references for further reading The book is aimed at a broad readership of scientific and medical professionals involved in research on cardiovascular diseases, pathophysiology, pharmacy, pharmaceutical science and life sciences. It also serves as a reference for scholars who want to understand the complex biochemical mechanisms of antioxidant agents.

Description based on publisher supplied metadata and other sources.

Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, 2024. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries.